Published in Infect Immun on October 01, 1998
A yeast under cover: the capsule of Cryptococcus neoformans. Eukaryot Cell (2003) 2.59
The capsule of the fungal pathogen Cryptococcus neoformans. Adv Appl Microbiol (2009) 1.97
Induction of capsule growth in Cryptococcus neoformans by mammalian serum and CO(2). Infect Immun (2003) 1.89
Capsule structure changes associated with Cryptococcus neoformans crossing of the blood-brain barrier. Am J Pathol (2005) 1.80
Synthesis of polymerized melanin by Cryptococcus neoformans in infected rodents. Infect Immun (2000) 1.79
Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection. Proc Natl Acad Sci U S A (2003) 1.71
Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations. Eukaryot Cell (2007) 1.63
Phenotypic switching in Cryptococcus neoformans results in changes in cellular morphology and glucuronoxylomannan structure. Infect Immun (1999) 1.60
The cryptococcal enzyme inositol phosphosphingolipid-phospholipase C confers resistance to the antifungal effects of macrophages and promotes fungal dissemination to the central nervous system. Infect Immun (2006) 1.60
Role of phagocytosis in the virulence of Cryptococcus neoformans. Eukaryot Cell (2004) 1.57
Molecular epidemiology of clinical Cryptococcus neoformans strains from India. J Clin Microbiol (2005) 1.53
Experimental modulation of capsule size in Cryptococcus neoformans. Biol Proced Online (2004) 1.52
Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival. Cell Microbiol (2008) 1.50
How sweet it is! Cell wall biogenesis and polysaccharide capsule formation in Cryptococcus neoformans. Annu Rev Microbiol (2009) 1.43
Cryptococcus neoformans capsule structure evolution in vitro and during murine infection. Infect Immun (2004) 1.31
Toward an integrated model of capsule regulation in Cryptococcus neoformans. PLoS Pathog (2011) 1.21
Radial mass density, charge, and epitope distribution in the Cryptococcus neoformans capsule. Eukaryot Cell (2006) 1.21
Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis. Cold Spring Harb Perspect Med (2014) 1.18
Antibody interactions with the capsule of Cryptococcus neoformans. Infect Immun (2000) 1.10
Phenotypic switching in a Cryptococcus neoformans variety gattii strain is associated with changes in virulence and promotes dissemination to the central nervous system. Infect Immun (2006) 1.05
The pathogenic fungus Cryptococcus neoformans expresses two functional GDP-mannose transporters with distinct expression patterns and roles in capsule synthesis. Eukaryot Cell (2007) 1.05
Role for chitin and chitooligomers in the capsular architecture of Cryptococcus neoformans. Eukaryot Cell (2009) 0.99
Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen. Infect Immun (2004) 0.98
Cryptococcus neoformans responds to mannitol by increasing capsule size in vitro and in vivo. Cell Microbiol (2010) 0.95
The elastic properties of the Cryptococcus neoformans capsule. Biophys J (2009) 0.94
Effects of antifungal interventions on the outcome of experimental infections with phenotypic switch variants of Cryptococcus neoformans. Antimicrob Agents Chemother (2005) 0.93
Effects of voriconazole on Cryptococcus neoformans. Antimicrob Agents Chemother (2004) 0.92
The still obscure attributes of cryptococcal glucuronoxylomannan. Med Mycol (2009) 0.92
Phenotypic switching in Cryptococcus neoformans contributes to virulence by changing the immunological host response. Infect Immun (2008) 0.90
Unusual galactofuranose modification of a capsule polysaccharide in the pathogenic yeast Cryptococcus neoformans. J Biol Chem (2013) 0.89
Altered immune response differentially enhances susceptibility to Cryptococcus neoformans and Cryptococcus gattii infection in mice expressing the HIV-1 transgene. Infect Immun (2013) 0.85
Cryptococcus neoformans Intracellular Proliferation and Capsule Size Determines Early Macrophage Control of Infection. Sci Rep (2016) 0.83
A unique alpha-1,3 mannosyltransferase of the pathogenic fungus Cryptococcus neoformans. J Bacteriol (1999) 0.82
Synthesis of cell envelope glycoproteins of Cryptococcus laurentii. Carbohydr Res (2007) 0.80
Fungal serotype-specific differences in bacterial-yeast interactions. Virulence (2015) 0.80
Does the Capsule Interfere with Performance of Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Identification of Cryptococcus neoformans and Cryptococcus gattii? J Clin Microbiol (2015) 0.79
Nitrogen source-dependent capsule induction in human-pathogenic cryptococcus species. Eukaryot Cell (2013) 0.78
Variability of phenotypic traits in Cryptococcus varieties and species and the resulting implications for pathogenesis. Future Microbiol (2010) 0.78
Aging as an emergent factor that contributes to phenotypic variation in Cryptococcus neoformans. Fungal Genet Biol (2014) 0.77
Of mice and men, revisited: new insights into an ancient molecule from studies of complement activation by Cryptococcus neoformans. Infect Immun (2006) 0.77
Aging: an emergent phenotypic trait that contributes to the virulence of Cryptococcus neoformans. Future Microbiol (2015) 0.76
Cryptococcus neoformans glucuronoxylomannan fractions of different molecular masses are functionally distinct. Future Microbiol (2014) 0.76
The Cryptococcus neoformans capsule: lessons from the use of optical tweezers and other biophysical tools. Front Microbiol (2015) 0.75
Cryptococcus neoformans UGT1 encodes a UDP-Galactose/UDP-GalNAc transporter. Glycobiology (2016) 0.75
Species in the Cryptococcus gattii Complex Differ in Capsule and Cell Size following Growth under Capsule-Inducing Conditions. mSphere (2016) 0.75
Physiological Differences in C. neoformans in vitro versus in vivo and Their Effects on Antifungal Susceptibility. Antimicrob Agents Chemother (2016) 0.75
Cryptococcus neoformans. I. Nonencapsulated mutants. J Bacteriol (1967) 5.15
Polysaccharide antigens of the capsule of Cryptococcus neoformans. Infect Immun (1994) 3.46
Effect of degree of encapsulation upon virulence of Cryptococcus neoformans. Proc Soc Exp Biol Med (1960) 3.06
Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J Infect Dis (1992) 2.98
Monoclonal antibody based ELISAs for cryptococcal polysaccharide. J Immunol Methods (1992) 2.97
Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. Clin Infect Dis (1994) 2.87
Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection. J Immunol (1997) 2.25
The mouse antibody response to infection with Cryptococcus neoformans: VH and VL usage in polysaccharide binding antibodies. J Exp Med (1991) 2.11
Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody. Infect Immun (1995) 1.79
Capsule synthesis by Cryptococcus neoformans. Trans N Y Acad Sci (1958) 1.76
A rapid fluorescent assay to distinguish attached from phagocytized yeast particles. J Immunol Methods (1987) 1.69
Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy. J Exp Med (1997) 1.60
Histochemical distribution of non-haem iron in the human brain. Acta Anat (Basel) (1992) 1.58
Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide. J Infect Dis (1998) 1.30
The distribution of iron in the brain: a phylogenetic analysis using iron histochemistry. Brain Res Dev Brain Res (1996) 0.91
Urease as a virulence factor in experimental cryptococcosis. Infect Immun (2000) 3.53
Cryptococcus neoformans melanin and virulence: mechanism of action. Infect Immun (1995) 3.43
Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection. Infect Immun (2000) 3.42
Cryptococcus neoformans var. grubii: separate varietal status for Cryptococcus neoformans serotype A isolates. J Clin Microbiol (1999) 3.38
Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. Proc Natl Acad Sci U S A (2001) 3.37
Intracellular parasitism of macrophages by Cryptococcus neoformans. Trends Microbiol (2001) 3.34
Persistence of initial infection in recurrent Cryptococcus neoformans meningitis. Lancet (1993) 3.34
Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun (1992) 3.21
Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. Mol Microbiol (2001) 3.02
Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. Clin Infect Dis (1994) 2.87
Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob Agents Chemother (1998) 2.74
Restriction fragment length polymorphism analysis of Cryptococcus neoformans isolates from environmental (pigeon excreta) and clinical sources in New York City. J Clin Microbiol (1994) 2.43
Susceptibility of melanized and nonmelanized Cryptococcus neoformans to nitrogen- and oxygen-derived oxidants. Infect Immun (1994) 2.41
Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics (2001) 2.40
Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection. J Immunol (1997) 2.25
Molecular epidemiology of Cryptococcus neoformans in Brazil and the United States: evidence for both local genetic differences and a global clonal population structure. J Clin Microbiol (1997) 2.19
Melanin, melanin "ghosts," and melanin composition in Cryptococcus neoformans. Infect Immun (1996) 2.15
Relationship between Arp2/3 complex and the barbed ends of actin filaments at the leading edge of carcinoma cells after epidermal growth factor stimulation. J Cell Biol (1999) 2.14
A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc Natl Acad Sci U S A (1998) 2.13
Microevolution of a standard strain of Cryptococcus neoformans resulting in differences in virulence and other phenotypes. Infect Immun (1998) 2.12
Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell. J Exp Med (1995) 2.11
Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect Immun (1995) 2.09
Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. J Exp Med (1993) 2.09
Dynamic changes in the morphology of Cryptococcus neoformans during murine pulmonary infection. Microbiology (2001) 2.08
Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice. Infect Immun (1994) 2.07
Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob Agents Chemother (1994) 2.00
Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob Agents Chemother (1997) 1.89
Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc Natl Acad Sci U S A (1993) 1.86
Mycobacterial infection of macrophages results in membrane-permeable phagosomes. Proc Natl Acad Sci U S A (1999) 1.84
Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat. Infect Immun (1994) 1.83
Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis. Clin Microbiol Rev (1998) 1.82
Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure. J Infect Dis (2008) 1.82
Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody. Infect Immun (1995) 1.79
Synthesis of polymerized melanin by Cryptococcus neoformans in infected rodents. Infect Immun (2000) 1.79
Monoclonal antibodies to surface antigens of Mycobacterium tuberculosis and their use in a modified enzyme-linked immunosorbent spot assay for detection of mycobacteria. J Clin Microbiol (1996) 1.76
T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice. Proc Natl Acad Sci U S A (1997) 1.72
Roles for inositol-phosphoryl ceramide synthase 1 (IPC1) in pathogenesis of C. neoformans. Genes Dev (2001) 1.72
Pathology of cryptococcal meningoencephalitis: analysis of 27 patients with pathogenetic implications. Hum Pathol (1996) 1.71
Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis. Infect Immun (1995) 1.70
Cellular charge of Cryptococcus neoformans: contributions from the capsular polysaccharide, melanin, and monoclonal antibody binding. Infect Immun (1997) 1.69
Enhancement of HIV-1 infection by the capsular polysaccharide of Cryptococcus neoformans. Lancet (1992) 1.67
Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody. J Immunol (1995) 1.67
Decreased susceptibility of melanized Cryptococcus neoformans to UV light. Appl Environ Microbiol (1994) 1.65
Laccase of Cryptococcus neoformans is a cell wall-associated virulence factor. Infect Immun (2001) 1.64
Phenotypic switching in Cryptococcus neoformans results in changes in cellular morphology and glucuronoxylomannan structure. Infect Immun (1999) 1.60
Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy. J Exp Med (1997) 1.60
Melanization of Cryptococcus neoformans in murine infection. Mol Cell Biol (1999) 1.59
Phenotypic switching in the human pathogenic fungus Cryptococcus neoformans is associated with changes in virulence and pulmonary inflammatory response in rodents. Proc Natl Acad Sci U S A (1998) 1.58
Radiological studies reveal radial differences in the architecture of the polysaccharide capsule of Cryptococcus neoformans. Eukaryot Cell (2005) 1.58
Karyotype instability in Cryptococcus neoformans infection. J Clin Microbiol (1996) 1.53
Growth of Cryptococcus neoformans in presence of L-dopa decreases its susceptibility to amphotericin B. Antimicrob Agents Chemother (1994) 1.53
Molecular epidemiology of clinical Cryptococcus neoformans strains from India. J Clin Microbiol (2005) 1.53
J774 murine macrophage-like cell interactions with Cryptococcus neoformans in the presence and absence of opsonins. J Infect Dis (1996) 1.51
Melanisation of Cryptococcus neoformans in human brain tissue. Lancet (2000) 1.50
Serum therapy for Cryptococcal meningitis. Clin Infect Dis (1995) 1.50
Melanin as a potential cryptococcal defence against microbicidal proteins. Med Mycol (1999) 1.48
Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans. Antimicrob Agents Chemother (1994) 1.48
Immunoglobulin M efficacy against Cryptococcus neoformans: mechanism, dose dependence, and prozone-like effects in passive protection experiments. J Immunol (2001) 1.42
The antibody response to fungal melanin in mice. J Immunol (1998) 1.42
Isolation and serological analyses of fungal melanins. J Immunol Methods (2000) 1.41
Biological correlates of capsular (quellung) reactions of Cryptococcus neoformans. J Immunol (2000) 1.39
Phenotypic switching of Cryptococcus neoformans occurs in vivo and influences the outcome of infection. J Clin Invest (2001) 1.38
The different binding patterns of two immunoglobulin M monoclonal antibodies to Cryptococcus neoformans serotype A and D strains correlate with serotype classification and differences in functional assays. Clin Diagn Lab Immunol (1998) 1.37
Prevalence of Cryptococcus neoformans var. neoformans (Serotype D) and Cryptococcus neoformans var. grubii (Serotype A) isolates in New York City. J Clin Microbiol (2000) 1.36
Extracellular proteinase activity of Cryptococcus neoformans. Clin Diagn Lab Immunol (1996) 1.36
Epidermal growth factor receptor distribution during chemotactic responses. Mol Biol Cell (2000) 1.34
Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans. Infect Immun (2001) 1.32
Detection of melanin-like pigments in the dimorphic fungal pathogen Paracoccidioides brasiliensis in vitro and during infection. Infect Immun (2001) 1.31
Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide. J Infect Dis (1998) 1.30
Serial isolates of Cryptococcus neoformans from patients with AIDS differ in virulence for mice. J Infect Dis (1998) 1.30
Reactive nitrogen intermediates in human neuropathology: an overview. Dev Neurosci (1994) 1.27
Reactivity patterns and epitope specificities of anti-Cryptococcus neoformans monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay. Infect Immun (1997) 1.27
Fungal morphogenesis and virulence. Med Mycol (2000) 1.26
Sterol composition of Cryptococcus neoformans in the presence and absence of fluconazole. Antimicrob Agents Chemother (1994) 1.26
Melanization affects susceptibility of Cryptococcus neoformans to heat and cold. FEMS Microbiol Lett (1997) 1.26
Cryptococcus neoformans survive and replicate in human microglia. Lab Invest (1995) 1.26
Antibody response to Cryptococcus neoformans proteins in rodents and humans. Infect Immun (1999) 1.26
Use of licensed vaccines for active immunization of the immunocompromised host. Clin Microbiol Rev (1998) 1.26
Genetic relationship between Cryptococcus neoformans var. neoformans strains of serotypes A and D. J Clin Microbiol (1998) 1.26
Sterol compositions and susceptibilities to amphotericin B of environmental Cryptococcus neoformans isolates are changed by murine passage. Antimicrob Agents Chemother (1995) 1.24
False-negative cerebrospinal fluid cryptococcal latex agglutination tests for patients with culture-positive cryptococcal meningitis. J Clin Microbiol (1993) 1.24
Evaluation of acute hematologic and long-term pulmonary toxicities of radioimmunotherapy of Cryptococcus neoformans infection in murine models. Antimicrob Agents Chemother (2004) 1.24
Serum cryptococcal antigen in patients with AIDS. Clin Infect Dis (1996) 1.24
Evidence that Cryptococcus neoformans is melanized in pigeon excreta: implications for pathogenesis. Infect Immun (1999) 1.23
Antigen-induced protective and nonprotective cell-mediated immune components against Cryptococcus neoformans. Infect Immun (1998) 1.23
DNA packing in filamentous bacteriophages. Annu Rev Biophys Biophys Chem (1988) 1.21
Expression of a Mycobacterium tuberculosis arabinomannan antigen in vitro and in vivo. Infect Immun (2001) 1.21
Immune complexes increase nitric oxide production by interferon-gamma- stimulated murine macrophage-like J774.16 cells. J Leukoc Biol (1995) 1.21
Immunohistochemical localization of capsular polysaccharide antigen in the central nervous system cells in cryptococcal meningoencephalitis. Am J Pathol (1996) 1.20
Immunoglobulin G3 blocking antibodies to the fungal pathogen Cryptococcus neoformans. J Exp Med (1996) 1.19
Passive immunization with melanin-binding monoclonal antibodies prolongs survival of mice with lethal Cryptococcus neoformans infection. Infect Immun (2001) 1.19
Extracellular proteins of Cryptococcus neoformans and host antibody response. Infect Immun (1997) 1.17
Human astrocytes inhibit Cryptococcus neoformans growth by a nitric oxide-mediated mechanism. J Exp Med (1994) 1.17
The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J Infect Dis (2000) 1.16